Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1073 - Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between Ocreotide in combination with Everolimus compared to Sunitinib

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Central Nervous System Malignancies

Presenters

Andres Cardona Zorrilla

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

A.F. Cardona Zorrilla1, A. Ruiz-Patiño1, O. Arrieta2, L. Zatarain-Barron2, F. Hakim3, E. Jimenez3, J.A. Mejia3, F. Ramon3, N. Useche4, S. Bermudez4, D. Pineda5, H. Cifuentes5, L.L. Rojas6, L.E. Pino Villareal7, C. Balana8

Author affiliations

  • 1 Translational Research, Foundation for Clinical and Applied Cancer Research, 110231 - Bogotá/CO
  • 2 Thoracic Oncology, Instituto Nacional de Cancerologia, 14080 - Mexico City/MX
  • 3 Neurosurgery, Fundacion Santa Fe de Bogota, Bogota/CO
  • 4 Neuroradiology, Fundacion Santa Fe de Bogota, Bogota/CO
  • 5 Neuroradiology, Clinica Del Country, Bogota/CO
  • 6 Clinical Oncology, Clinica Colsanitas, 110231 - Bogotá/CO
  • 7 Clinical Oncology, Fundacion Santa Fe de Bogota, Bogota/CO
  • 8 Neuro-oncology Section, Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
More

Resources

Abstract 1073

Background

Anaplastic and atypical recurrent meningioma constitute a rare pathology with very few available effective systemic treatments.

Methods

A comprehensive analysis of 31 patients with atypical (WHO II) or anaplastic meningiomas (WHO III) that were recurrent and refractory to radiotherapy was conducted in two reference centers of Colombia. Only patients who had received some systemic treatment (sunitinib, everolimus/octeotride and bevacizumab) and had a complete follow-up were included. Overall survival (OS), progression free survival and toxicities were evaluated. Additionally, tissue samples were examined for PDGFRa and VEGFR2 and its expression was correlated with outcomes.

Results

Twenty two patients (72%) were females with a median age of 55 years (SD ± 15.3). The most prevalent histology was anaplastic meningioma in 20 patients (65%) with 48% of patients suffering from three previous relapses before the start of systemic treatment. A total of 14 patients received combination therapy with octeotride/everolimus, 11 received sunitinib and the remaining 6 other second line agents. Median OS was 37.3 months (95%CI 28.5-42.1) and the PFS during the treatment with everolimus/octeotride (EO) and sunitinib (Su) was 12.1 months (95%CI 9.2-21.1) and 9.1 months (95%CI 6.8-16.8); p = 0.43), respectively. The OS of the group treated with the EO→Su→Bev sequence (1st/2nd/3rd line) was 6.5 months longer than the Su→EO→Bev sequence, a finding that was not significant (36.0 vs. 29.5 months; p = 0.349). When analyzing molecular markers, the positive PDGFRa and negative VEGFR2 expression were associated with longer survival both in OS and PFS.

Conclusions

Sunitinib and ocreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRa expression are strongly associated with major survival endpoints.

Clinical trial identification

Legal entity responsible for the study

Foundation for Clinical and Applied Cancer Research – FICMAC

Funding

Supported by the Foundation for Clinical and Applied Cancer Research - FICMAC (Bogotá Colombia) research grant 011-2017SD.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.